Elevance Health, Inc. $ELV Shares Sold by Quadrant Capital Group LLC

Quadrant Capital Group LLC cut its position in Elevance Health, Inc. (NYSE:ELV) by 34.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,846 shares of the company’s stock after selling 1,529 shares during the quarter. Quadrant Capital Group LLC’s holdings in Elevance Health were worth $1,210,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of ELV. Pinnacle Associates Ltd. grew its position in shares of Elevance Health by 7.4% during the 3rd quarter. Pinnacle Associates Ltd. now owns 2,922 shares of the company’s stock valued at $1,136,000 after purchasing an additional 201 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its position in shares of Elevance Health by 94.0% in the third quarter. Robeco Institutional Asset Management B.V. now owns 332,778 shares of the company’s stock worth $129,391,000 after buying an additional 161,278 shares in the last quarter. Revisor Wealth Management LLC boosted its stake in Elevance Health by 6.6% during the third quarter. Revisor Wealth Management LLC now owns 4,404 shares of the company’s stock valued at $1,801,000 after buying an additional 274 shares during the period. Bank Pictet & Cie Europe AG grew its position in Elevance Health by 5.8% during the third quarter. Bank Pictet & Cie Europe AG now owns 1,654 shares of the company’s stock worth $643,000 after buying an additional 90 shares in the last quarter. Finally, 55 North Private Wealth LLC increased its stake in Elevance Health by 4.5% in the 3rd quarter. 55 North Private Wealth LLC now owns 598 shares of the company’s stock worth $233,000 after acquiring an additional 26 shares during the last quarter. 89.24% of the stock is owned by institutional investors.

Elevance Health Price Performance

Shares of NYSE:ELV opened at $440.05 on Friday. The company has a quick ratio of 1.52, a current ratio of 1.47 and a debt-to-equity ratio of 0.68. The stock has a market cap of $95.43 billion, a PE ratio of 18.77, a PEG ratio of 2.32 and a beta of 0.70. The company’s fifty day moving average is $408.32 and its 200 day moving average is $390.89. Elevance Health, Inc. has a 52 week low of $274.84 and a 52 week high of $450.69.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 EPS for the quarter, topping analysts’ consensus estimates of $4.71 by $2.28. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The business had revenue of $50.44 billion for the quarter, compared to analysts’ expectations of $49.28 billion. During the same period in the previous year, the firm earned $6.03 EPS. The business’s quarterly revenue was up .7% on a year-over-year basis. Research analysts anticipate that Elevance Health, Inc. will post 27.09 earnings per share for the current year.

Elevance Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be paid a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, December 4th. Elevance Health’s payout ratio is presently 29.34%.

Elevance Health News Roundup

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Third-quarter adjusted earnings per share rose 15.9% and exceeded consensus, while revenue also topped expectations. Elevance raised its 2026 adjusted EPS outlook to at least $29, citing disciplined cost management and improved medical-cost trends. Elevance Health Q3 Results
• Positive Sentiment: Carelon’s expansion and clinical programs remain growth drivers; its cancer program reportedly reduced avoidable inpatient admissions by 15%. Management also highlighted actions intended to improve Medicaid profitability. ELV Q3 Deep Dive
• Positive Sentiment: TD Cowen raised its price target to $495 from $465 and maintained a Buy rating, indicating continued confidence in the earnings recovery. TD Cowen Rating
• Positive Sentiment: Elevance declared a quarterly dividend of $1.72 per share, supporting its shareholder-return profile. Elevance Health Dividend
• Neutral Sentiment: Elevance appointed Jeff Park as president of Carelon in a services leadership shift. The move may support execution, but its financial impact is not yet clear. Carelon Leadership Shift
• Neutral Sentiment: Morgan Stanley lifted its target to $449 from $404 but retained an Equal Weight rating, suggesting limited upside after the recent advance. Morgan Stanley Rating
• Negative Sentiment: Officer Mark B. Kaye disclosed an intent to sell 10,584 shares valued at approximately $4.66 million. While the sale may be routine, it can weigh on sentiment near a 52-week high. Officer Share Sale
• Negative Sentiment: Analysts continue to flag sustainability risks: nine-month operating gain declined, and Medicaid margins remain under pressure. Robert W. Baird kept a Neutral rating with a $406 target, below the current trading level. Elevance Health Earnings Analysis

Wall Street Analyst Weigh In

ELV has been the subject of several recent analyst reports. The Goldman Sachs Group reissued a “neutral” rating and set a $451.00 price objective on shares of Elevance Health in a report on Friday. Mizuho set a $490.00 target price on shares of Elevance Health in a research report on Friday. Cantor Fitzgerald boosted their price target on shares of Elevance Health from $400.00 to $450.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 7th. Wall Street Zen lowered shares of Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, Royal Bank Of Canada raised their price objective on shares of Elevance Health from $424.00 to $455.00 and gave the company a “sector perform” rating in a research report on Thursday. Fifteen analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, Elevance Health presently has an average rating of “Moderate Buy” and an average price target of $455.57.

Insider Activity at Elevance Health

In related news, CFO Mark Kaye sold 10,584 shares of the company’s stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the completion of the sale, the chief financial officer directly owned 19,919 shares in the company, valued at $8,766,949.47. This represents a 34.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.34% of the stock is currently owned by insiders.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.